Table 2. Overall response rates reported... | American Society of Hematology

Table 2.

Overall response rates reported for FDA-approved agents for AITL vs PTCL-NOS

Subtype	Pralatrexate	Romidepsin	Belinostat
PTCL-NOS, %	32	29	23
AITL, %	8	30	46

PTCL-NOS, peripheral T-cell lymphoma, not otherwise specified.